GNI Group Ltd. - 26 Dec 2022 Form 3 Insider Report for CATALYST BIOSCIENCES, INC. (GYRE)

Role
10%+ Owner
Signature
/s/ Branden Berns, Attorney-in-fact for GNI Group Ltd.
Issuer symbol
GYRE
Transactions as of
26 Dec 2022
Net transactions value
$0
Form type
3
Filing time
05 Jan 2023, 15:06:09 UTC
Next filing
01 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CBIO Common Stock 895,217 26 Dec 2022 Direct F1, F2
holding CBIO Common Stock 5,371,304 26 Dec 2022 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CBIO Series X Convertible Preferred Stock 26 Dec 2022 Common Stock 17,630,000 Direct F1, F2, F5
holding CBIO Series X Convertible Preferred Stock 26 Dec 2022 Common Stock 105,770,000 Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are held by GNI Group Ltd. ("GNI Japan").
F2 GNI Hong Kong Ltd. ("GNI HK") disclaims beneficial ownership of the securities held by GNI Japan for purposes of Rule 16a-1(a)(2), except to the extent of its pecuniary interest therein.
F3 These securities are held by GNI HK.
F4 GNI HK, through GNI Japan-affiliated entities, is a wholly-owned subsidiary of GNI Japan. GNI Japan may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the securities held by GNI HK and, therefore, a "ten percent holder" hereunder.
F5 Shares of Series X Convertible Preferred Stock, par value $0.001 per share (the "Preferred Stock"), are convertible into common stock based on the Conversion Ratio and subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for the Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on December 27, 2022), at the holder's election after 5:00 p.m. (New York City time) on the second business day after the date on which the Issuer's stockholders approve the conversion of the Preferred Stock.

Remarks:

Exhibit 24.1 - Power of Attorney Exhibit 24.2 - Power of Attorney